Cyllene Therapeutics secured a $37 million Series C to push EG110A into late-stage development for severe neurogenic bladder. The financing is earmarked for advancing the company’s lead gene therapy candidate and supporting further clinical execution as it targets a high-unmet-need urology population. For investors, the round underscores continued appetite for late-moving gene and cell approaches in CNS-adjacent and neuromuscular indications, where durability and functional outcomes are central to differentiation.